Elizabeth D. Tate
Research Subjects
Elizabeth D. Tate has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Michael R. Pranzatelli
National Pediatric Myoclonus Center and National Pediatric Neuroinflammation Organization, Inc., Orlando, FL, USA
5 shared publications - Nathan R. McGee
National Pediatric Myoclonus Center and Neuroimmunology Research Laboratory, P.O. Box 19643, Springfield, IL 62794-9643, USA
3 shared publications - Anna L. Travelstead
Flow Cytometry Facility, Southern Illinois University School of Medicine, Springfield, IL 62794-9626, USA
2 shared publications - Richard M. Ransohoff
Third Rock Ventures, Boston, MA, USA
2 shared publications David Neal Franz
Departments of Pediatrics and Neurology, University of Cincinnati College of Medicine, Cincinnati, OH, USA
1 shared publication- Jayne M. Ness
Department of Pediatrics, University of Alabama at Birmingham School of Medicine, Birmingham, AL, 35233, USA
1 shared publication
Latest Publications
- 11 October 2017
- Published by Elsevier in Pediatric Neurology
- Vol. 78, e3
Response to Sharawat and Suther
- 11 October 2017
- Published by Elsevier in Pediatric Neurology
- Vol. 78, e3
Response to Sharawat and Suther
- Open Access
- 16 January 2013
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 10 (1) , 10
BAFF/APRIL system in pediatric OMS: relation to severity, neuroinflammation, and immunotherapy
B-cell dysregulation has been implicated but not fully characterized in pediatric opsoclonus-myoclonus syndrome (OMS), a neuroblastoma-associated neuroinflammatory disorder.
- 16 January 2013
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 10 (1) , 10
Open AccessBAFF/APRIL system in pediatric OMS: relation to severity, neuroinflammation, and immunotherapy
B-cell dysregulation has been implicated but not fully characterized in pediatric opsoclonus-myoclonus syndrome (OMS), a neuroblastoma-associated neuroinflammatory disorder.
- 28 February 2012
- Published by SAGE Publications in Journal of Child Neurology
- Vol. 27 (7) , 875-884
Active Comparator-Controlled, Rater-Blinded Study of Corticotropin-Based Immunotherapies for Opsoclonus-Myoclonus Syndrome
To test the efficacy and safety of corticotropin-based immunotherapies in pediatric opsoclonus-myoclonus syndrome, 74 children received corticotropin alone or with intravenous immunoglobulin (groups 1 and 2, active controls); or both with rituximab (group 3) or cyclophosphamide (group 4); or with rituximab plus chemotherapy (group 5) or steroid sparers (group 6). There was 65% improvement in motor severity score across groups (P < .0001), but treatment combinations were more effective than corticotropin alone (P = .0009). Groups 3, 4, and 5 responded better than group 1; groups 3 and 5 responded better than group 2. The response frequency to corticotropin was higher than to prior corticosteroids (P < .0001). Fifty-five percent had adverse events (corticosteroid excess), more so with multiagents (P = .03); and 10% had serious adverse events. This study demonstrates greater efficacy of corticotropin-based multimodal therapy compared with conventional therapy, greater response to corticotropin than corticosteroid-based therapy, and overall tolerability.
- 28 February 2012
- Published by SAGE Publications in Journal of Child Neurology
- Vol. 27 (7) , 875-884
Active Comparator-Controlled, Rater-Blinded Study of Corticotropin-Based Immunotherapies for Opsoclonus-Myoclonus Syndrome
To test the efficacy and safety of corticotropin-based immunotherapies in pediatric opsoclonus-myoclonus syndrome, 74 children received corticotropin alone or with intravenous immunoglobulin (groups 1 and 2, active controls); or both with rituximab (group 3) or cyclophosphamide (group 4); or with rituximab plus chemotherapy (group 5) or steroid sparers (group 6). There was 65% improvement in motor severity score across groups (P < .0001), but treatment combinations were more effective than corticotropin alone (P = .0009). Groups 3, 4, and 5 responded better than group 1; groups 3 and 5 responded better than group 2. The response frequency to corticotropin was higher than to prior corticosteroids (P < .0001). Fifty-five percent had adverse events (corticosteroid excess), more so with multiagents (P = .03); and 10% had serious adverse events. This study demonstrates greater efficacy of corticotropin-based multimodal therapy compared with conventional therapy, greater response to corticotropin than corticosteroid-based therapy, and overall tolerability.
- 1 January 2005
- Published by SAGE Publications in Journal of Pediatric Oncology Nursing
- Vol. 22 (1) , 8-19
Neuroepidemiologic Trends in 105 US Cases of Pediatric Opsoclonus-Myoclonus Syndrome
Opsoclonus-myoclonus syndrome (OMS) is a rare, autoimmune neurological disorder that is poorly recognized and undertreated. Neuroblastoma is found in one half of the cases. Because of the high incidence of spontaneous regression of neuroblastoma, it is unknown whether not finding a tumor means there was none. To define demographic trends and the standard of care in the first large series of OMS, 105 children were recruited over a 13-year period in a retrospective questionnaire survey. Children with and without a tumor differed little in viral-like prodrome and neurological symptoms. Earliest neurological symptoms were staggering and falling, leading to a misdiagnosis of acute cerebellitis. Later symptoms included body jerks, drooling, refusal to walk or sit, speech problems, decreased muscle tone, opsoclonus, and inability to sleep. Tumor resection alone did not provide adequate therapy for most. Adrenocorticotropic hormone (ACTH), prednisone, and intravenous immunoglobulin were used with equal frequency, but ACTH was associated with the best early response. More than one half of the children had relapses. Residual behavioral, language, and cognitive problems occurred in the majority. The delay in diagnosis (11 weeks) and initiation of treatment (17 weeks) is unacceptably long.
- 1 January 2005
- Published by SAGE Publications in Journal of Pediatric Oncology Nursing
- Vol. 22 (1) , 8-19
Neuroepidemiologic Trends in 105 US Cases of Pediatric Opsoclonus-Myoclonus Syndrome
Opsoclonus-myoclonus syndrome (OMS) is a rare, autoimmune neurological disorder that is poorly recognized and undertreated. Neuroblastoma is found in one half of the cases. Because of the high incidence of spontaneous regression of neuroblastoma, it is unknown whether not finding a tumor means there was none. To define demographic trends and the standard of care in the first large series of OMS, 105 children were recruited over a 13-year period in a retrospective questionnaire survey. Children with and without a tumor differed little in viral-like prodrome and neurological symptoms. Earliest neurological symptoms were staggering and falling, leading to a misdiagnosis of acute cerebellitis. Later symptoms included body jerks, drooling, refusal to walk or sit, speech problems, decreased muscle tone, opsoclonus, and inability to sleep. Tumor resection alone did not provide adequate therapy for most. Adrenocorticotropic hormone (ACTH), prednisone, and intravenous immunoglobulin were used with equal frequency, but ACTH was associated with the best early response. More than one half of the children had relapses. Residual behavioral, language, and cognitive problems occurred in the majority. The delay in diagnosis (11 weeks) and initiation of treatment (17 weeks) is unacceptably long.